1. Home
  2. KLXE vs SKYE Comparison

KLXE vs SKYE Comparison

Compare KLXE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLXE
  • SKYE
  • Stock Information
  • Founded
  • KLXE 2018
  • SKYE 2012
  • Country
  • KLXE United States
  • SKYE United States
  • Employees
  • KLXE N/A
  • SKYE N/A
  • Industry
  • KLXE Oilfield Services/Equipment
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • KLXE Energy
  • SKYE Health Care
  • Exchange
  • KLXE Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • KLXE 89.2M
  • SKYE 80.7M
  • IPO Year
  • KLXE N/A
  • SKYE N/A
  • Fundamental
  • Price
  • KLXE $4.54
  • SKYE $3.14
  • Analyst Decision
  • KLXE Hold
  • SKYE Buy
  • Analyst Count
  • KLXE 1
  • SKYE 6
  • Target Price
  • KLXE $4.50
  • SKYE $18.67
  • AVG Volume (30 Days)
  • KLXE 191.8K
  • SKYE 178.7K
  • Earning Date
  • KLXE 03-05-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • KLXE N/A
  • SKYE N/A
  • EPS Growth
  • KLXE N/A
  • SKYE N/A
  • EPS
  • KLXE N/A
  • SKYE N/A
  • Revenue
  • KLXE $738,000,000.00
  • SKYE N/A
  • Revenue This Year
  • KLXE N/A
  • SKYE N/A
  • Revenue Next Year
  • KLXE $4.79
  • SKYE N/A
  • P/E Ratio
  • KLXE N/A
  • SKYE N/A
  • Revenue Growth
  • KLXE N/A
  • SKYE N/A
  • 52 Week Low
  • KLXE $4.18
  • SKYE $2.31
  • 52 Week High
  • KLXE $9.80
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • KLXE 35.29
  • SKYE 52.82
  • Support Level
  • KLXE $5.04
  • SKYE $2.70
  • Resistance Level
  • KLXE $6.16
  • SKYE $3.29
  • Average True Range (ATR)
  • KLXE 0.51
  • SKYE 0.45
  • MACD
  • KLXE -0.19
  • SKYE 0.05
  • Stochastic Oscillator
  • KLXE 2.15
  • SKYE 41.27

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: